FindMyKOL
Clinical trialNCT04230954TerminatedPhase 2Interventional

Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

NCT04230954 is a phase 2 interventional trial sponsored by University of South Alabama. As of 21 Nov 2026, it was terminated. It studies Cabozantinib and Pembrolizumab in Cervical Cancer, Metastatic Cervical Cancer and 2 more conditions. The registry lists an enrollment of 5 participants at 1 site in 1 country. The registry lists a start date of 16 Apr 2020 and a primary completion date of 16 Feb 2022.

SponsorUniversity of South Alabama →Enrollment5Cervical CancerMetastatic Cervical CancerPersistent Cervical CancerRecurrent Cervical Cancer
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT04230954
FieldValue
Registry IDNCT04230954
StatusTerminated
PhasePhase 2
Study typeInterventional trial
Lead sponsorUniversity of South Alabama
Enrollment5
Registered sites1
Countries1
ConditionsCervical Cancer, Metastatic Cervical Cancer, Persistent Cervical Cancer and Recurrent Cervical Cancer
DrugsCabozantinib and Pembrolizumab
Start16 Apr 2020
Primary completion16 Feb 2022
Study completion16 Feb 2022
Last update posted7 Jun 2022

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Drug: Cabozantinib Drug: Pembrolizumab

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Alabama, United States1 site
  • University of South Alabama Mitchell Cancer Institute

    Mobile

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabama: 1 siteAL1GeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT04230954

Each answer restates registry values shown on this page.

What is NCT04230954?

NCT04230954 is a phase 2 interventional trial sponsored by University of South Alabama. It studies Cabozantinib and Pembrolizumab in Cervical Cancer, Metastatic Cervical Cancer and 2 more conditions.

Who leads NCT04230954?

The registry names Stefanie White (study director, University of South Alabama) as the overall official.

Where does NCT04230954 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT04230954 study?

The registered drug and biological interventions are Cabozantinib and Pembrolizumab.

When did NCT04230954 end?

The registry lists a primary completion date of 16 Feb 2022 and a study completion date of 16 Feb 2022. The sponsor last updated the record on 7 Jun 2022.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.